Literature DB >> 31353240

Structural Basis of the Differential Binding of Engineered Knottins to Integrins αVβ3 and α5β1.

Johannes F Van Agthoven1, Hengameh Shams2, Frank V Cochran3, José L Alonso1, James R Kintzing3, Kiavash Garakani2, Brian D Adair1, Jian-Ping Xiong1, Mohammad R K Mofrad2, Jennifer R Cochran3, M Amin Arnaout4.   

Abstract

Targeting both integrins αVβ3 and α5β1 simultaneously appears to be more effective in cancer therapy than targeting each one alone. The structural requirements for bispecific binding of ligand to integrins have not been fully elucidated. RGD-containing knottin 2.5F binds selectively to αVβ3 and α5β1, whereas knottin 2.5D is αVβ3 specific. To elucidate the structural basis of this selectivity, we determined the structures of 2.5F and 2.5D as apo proteins and in complex with αVβ3, and compared their interactions with integrins using molecular dynamics simulations. These studies show that 2.5D engages αVβ3 by an induced fit, but conformational selection of a flexible RGD loop accounts for high-affinity selective binding of 2.5F to both integrins. The contrasting binding of the highly flexible low-affinity linear RGD peptides to multiple integrins suggests that a "Goldilocks zone" of conformational flexibility of the RGD loop in 2.5F underlies its selective binding promiscuity to integrins.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  NMR; cancer diagnosis; cancer therapy; cell adhesion; conformational flexibility; integrins; molecular dynamics; protein crystallography; receptors/structure-function

Year:  2019        PMID: 31353240      PMCID: PMC6726563          DOI: 10.1016/j.str.2019.06.011

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  41 in total

Review 1.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

2.  Mechanically activated integrin switch controls alpha5beta1 function.

Authors:  Julie C Friedland; Mark H Lee; David Boettiger
Journal:  Science       Date:  2009-01-30       Impact factor: 47.728

Review 3.  The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.

Authors:  Barry S Coller; Sanford J Shattil
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

4.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

5.  End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Authors:  Warren P Mason
Journal:  Neuro Oncol       Date:  2015-02-13       Impact factor: 12.300

Review 6.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

7.  Torsion angle dynamics for NMR structure calculation with the new program DYANA.

Authors:  P Güntert; C Mumenthaler; K Wüthrich
Journal:  J Mol Biol       Date:  1997-10-17       Impact factor: 5.469

8.  Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.

Authors:  Hae Sook Park; Choonmi Kim; Young Kee Kang
Journal:  Biopolymers       Date:  2002-04-15       Impact factor: 2.505

9.  Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.

Authors:  Patrick T Caswell; May Chan; Andrew J Lindsay; Mary W McCaffrey; David Boettiger; Jim C Norman
Journal:  J Cell Biol       Date:  2008-10-06       Impact factor: 10.539

Review 10.  The integrins.

Authors:  Yoshikazu Takada; Xiaojing Ye; Scott Simon
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  4 in total

1.  Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

Authors:  Caitlyn L Miller; Idit Sagiv-Barfi; Patrick Neuhöfer; Debra K Czerwinski; Steven E Artandi; Carolyn R Bertozzi; Ronald Levy; Jennifer R Cochran
Journal:  Cell Chem Biol       Date:  2021-11-12       Impact factor: 9.039

2.  Conformational Dynamics in Extended RGD-Containing Peptides.

Authors:  William R Lindemann; Alexander J Mijalis; José L Alonso; Peter P Borbat; Jack H Freed; M Amin Arnaout; Bradley L Pentelute; Julia H Ortony
Journal:  Biomacromolecules       Date:  2020-06-16       Impact factor: 6.988

3.  Characterization Of Blood-Brain Barrier Crossing And Tumor Homing Peptides By Molecular Dynamics Simulations.

Authors:  Caterina Arcangeli; Chiara Lico; Selene Baschieri; Mariateresa Mancuso
Journal:  Int J Nanomedicine       Date:  2019-12-30

4.  Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade.

Authors:  Chensu Wang; Ang Cui; Maurice Bukenya; Aereas Aung; Dikshant Pradhan; Charles A Whittaker; Yash Agarwal; Ayush Thomas; Simon Liang; Parastoo Amlashi; Heikyung Suh; Stefani Spranger; Nir Hacohen; Darrell J Irvine
Journal:  Cell Rep       Date:  2021-11-23       Impact factor: 9.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.